New Product & Service Launches, Collaborations and Quarterly Earnings Schedules - Research Report on Valeant, Lilly, Dr.

    New Product & Service Launches, Collaborations and Quarterly Earnings
Schedules - Research Report on Valeant, Lilly, Dr. Reddy's, Celgene and Vertex

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, July 11, 2013

NEW YORK, July 11, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Valeant
Pharmaceuticals Intl. Inc. (NYSE: VRX), Eli Lily & Co. (NYSE: LLY), Dr.
Reddy's Laboratories Limited (NYSE: RDY), Celgene Corporation (NASDAQ: CELG)
and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Valeant Pharmaceuticals Intl. Inc. Research Report

On July 2, 2013, Medicis, a division of Valeant Pharmaceuticals International,
Inc. (Valeant), announced a collaboration with Mentor Worldwide LLC, to enter
certain of their non-reimbursed products into a combined physician loyalty
program called M2VP (Medicis-Mentor Valued Partner). M2VP extends the
offerings of Medicis' recently-launched MVP program to include the MENTOR line
of breast implant products for a five-year term, and offers numerous
incentives that reward the use of various products across the Mentor and
Medicis portfolios. The program allows participating members not only to earn
points but to redeem them for items such as product purchases. "With this
program we are providing our customers with opportunities for volume-based
cost savings on the products they use and added incentives to try other
products from our combined portfolios," said Ryan Weldon, President of
Medicis. "We believe that the M2VP program is one of the most comprehensive
loyalty programs in the industry and will bring value to all practices, both
large and small. The addition of Mentor's breast aesthetic portfolio is truly
exciting news for our customers and we are excited about future iterations of
the program to come." The Full Research Report on Valeant Pharmaceuticals
Intl. Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/94d5_VRX]

--

Eli Lily & Co. Research Report

On July 8, 2013, Eli Lilly & Co. (Lilly) announced the return of John C.
Lechleiter, Ph. D., as Lilly's Chairman, President and CEO. Lechleiter had
been on medical leave since his scheduled surgery for a dilated aorta on May
13, 2013. "I am overwhelmed and humbled by the tremendous support and
well-wishes I have received from my friends and fellow Lilly colleagues around
the world," Lechleiter said. "I return to Lilly with renewed energy and
enthusiasm, along with a new perspective on health and wellness and the
critical importance of new medicines in advancing patient care." Lechleiter's
surgery and recovery were successful and he has been cleared by his personal
physician and the Company's employee health services physician to return to
full-time work. Lilly EVP Derica Rice served as acting CEO during Lechleiter's
leave. The Full Research Report on Eli Lily & Co. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/937b_LLY]

--

Dr. Reddy's Laboratories Limited Research Report

On June 26, 2013, Dr. Reddy's Laboratories Limited (Dr. Reddy's) announced the
launch of Lamotrigine Extended-Release Tablets (in 25, 50, 100, 200 and 300
mg), a therapeutic equivalent generic version of Lamictal XR (lamotrgine) in
the US market on June 25, 2013, following US FDA approval of the Company's
ANDA for Lamotrigine XR tablets. According to IMS Health, the Lamictal XR
brand and generic had combined U.S. sales of approximately $300.5 million MAT
for the most recent twelve months ending in April 2013. The Full Research
Report on Dr. Reddy's Laboratories Limited - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/e286_RDY]

--

Celgene Corporation Research Report

On July 8, 2013, Celgene Corporation (Celgene) will discuss its Q2 2013
financial results via a conference call and live audio webcast on Thursday,
July 25, 2013 at 9:00 a.m. ET. The webcast can be accessed at the Company's
website. The Full Research Report on Celgene Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/7541_CELG]

--

Vertex Pharmaceuticals Incorporated Research Report

On June 27, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced it
will report its Q2 2013 financial results on Monday, July 29, 2013 after the
market close via a conference call and webcast at 5:00 p.m. ET. The conference
call will be webcast live and a link to the webcast may be accessed from the
"Vertex Events" page of Vertex's website. A replay of the conference call and
webcast will be archived on the company's website until August 5, 2013. The
Full Research Report on Vertex Pharmaceuticals Incorporated - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/ec92_VRTX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: Contact: WSReports.com Phone #: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.